Safety and Efficacy of Drug Combinations Against Trichuris Trichiura
NCT ID: NCT01050452
Last Updated: 2010-01-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
750 participants
INTERVENTIONAL
2007-10-31
2009-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety and Efficacy of Drug Combinations Against Triple Infections
NCT01050517
Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
NCT02078024
Safety and Efficacy of Drug Combinations Against Schistosomiasis
NCT01050374
IVM Alone vs ALB + IVM Against Onchocerciasis
NCT03238131
Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness
NCT06282315
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
albendazole treatment
albendazole
albendazole (400 mg on dose)
2
mebendazole treatment
mebendazole
mebendazole (500 mg one dose)
3
ivermectin treatment
ivermectin
ivermectin (200 microgram/kg body weight)
4
albendazole + ivermectin treatment
albendazole + ivermectin
albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
5
mebendazole + ivermectin treatment
mebendazole + ivermectin
mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
albendazole
albendazole (400 mg on dose)
mebendazole
mebendazole (500 mg one dose)
ivermectin
ivermectin (200 microgram/kg body weight)
albendazole + ivermectin
albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
mebendazole + ivermectin
mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are infected with T. trichiura
* Whose parent consent and who are willing to participate
Exclusion Criteria
* Those with a history of any serious adverse drug reactions
5 Years
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
DBL -Institute for Health Research and Development
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Vector control division, Ministry of Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Vector Control Division
Kampala, , Uganda
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Namwanje H, Kabatereine NB, Olsen A. Efficacy of single and double doses of albendazole and mebendazole alone and in combination in the treatment of Trichuris trichiura in school-age children in Uganda. Trans R Soc Trop Med Hyg. 2011 Oct;105(10):586-90. doi: 10.1016/j.trstmh.2011.07.009. Epub 2011 Aug 31.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DBL-CHRD
Identifier Type: -
Identifier Source: secondary_id
AO.UGA.TRI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.